Remus Pharmaceuticals Ltd

Remus Pharmaceuticals Ltd

₹ 2,512 -1.74%
11 Dec 3:47 p.m.
About

Incorporated in 2015, Remus Pharma Ltd is in the business of trading and export of API and Finished Formulations and in Technical consultancy services[1]

Key Points

Busienss Overview:[1][2]
RPL and its group of companies specialize in marketing pharmaceutical products with expertise in Critical Care, Neurology, Cardiology, and Diabetic categories, and recently getting off-patent molecules in various dosage forms and in complex generics. Company gets finished pharmaceutical formulations manufactured on loan license or contract manufacturing

  • Market Cap 1,480 Cr.
  • Current Price 2,512
  • High / Low 2,835 / 1,200
  • Stock P/E 52.4
  • Book Value 171
  • Dividend Yield 0.06 %
  • ROCE %
  • ROE %
  • Face Value 10.0

Pros

Cons

  • Stock is trading at 14.7 times its book value
  • Company has high debtors of 197 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Half Yearly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2023 Mar 2024 Sep 2024
29 183 273
20 165 252
Operating Profit 9 19 20
OPM % 32% 10% 8%
2 6 3
Interest 0 0 1
Depreciation 0 0 0
Profit before tax 10 24 22
Tax % 25% 14% 16%
6 20 19
EPS in Rs 9.58 26.93 23.78
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2024 TTM
212 456
185 417
Operating Profit 28 39
OPM % 13% 9%
5 9
Interest 0 1
Depreciation 1 1
Profit before tax 32 46
Tax % 18%
26 39
EPS in Rs 36.51 50.71
Dividend Payout % 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: %
TTM: %
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: %
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: 87%
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: %

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2024 Sep 2024
Equity Capital 1 6
Reserves 85 95
12 21
159 100
Total Liabilities 257 221
12 13
CWIP 0 1
Investments 23 21
223 187
Total Assets 257 221

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2024
4
-9
24
Net Cash Flow 19

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2024
Debtor Days 197
Inventory Days 95
Days Payable 208
Cash Conversion Cycle 84
Working Capital Days 68
ROCE %

Shareholding Pattern

Numbers in percentages

2 Recently
Sep 2023Mar 2024Jun 2024Sep 2024
69.61% 70.60% 70.66% 70.84%
2.38% 3.25% 3.00% 3.16%
0.71% 0.67% 0.73% 0.77%
27.30% 25.49% 25.61% 25.22%
No. of Shareholders 8561,1241,5771,753

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents